Dabigatran
Pradaxa (dabigatran) is a small molecule pharmaceutical. Dabigatran was first approved as Pradaxa on 2008-03-17. It has been approved in Europe to treat replacement arthroplasty and venous thromboembolism. The pharmaceutical is active against prothrombin. Pradaxa's patents are valid until 2031-01-20 (FDA).
Trade Name | Pradaxa |
---|---|
Common Name | Dabigatran |
Indication | replacement arthroplasty, venous thromboembolism |
Drug Class | Thrombin inhibitors (argatroban type) |